Physician profile
Alexandra Piper
NPI 1720519002
$1,114.95
in general payments reported to CMS, 2019-2025
14 companies · $98.31 in 2025
The $98.31 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $103 · 2021: $300 · 2022: $270 · 2023: $76.77 · 2024: $62.08 · 2025: $98.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $219 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $219.32 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $364.97 | 2019-2024 | Rocklatan |
| Oyster Point Pharma, INC. | $147.76 | 2022-2023 | Tyrvaya |
| Sight Sciences, INC. | $146.11 | 2021 | |
| Allergan, INC. | $86.67 | 2021 | |
| Bausch & Lomb Americas INC. | $84.57 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Harrow Eye, LLC | $56.89 | 2024-2025 | Vevye |
| Coopervision INC. | $48.26 | 2019-2023 | Paragon Crt |
| Johnson & Johnson Surgical Vision, INC. | $45.04 | 2021-2022 | |
| Ivantis, INC | $35.90 | 2021 | |
| Dompe US, INC. | $27.98 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $22.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.08 | 2021 | |
| Abbvie INC. | $16.49 | 2022 | |
| Horizon Therapeutics Plc | $14.96 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Piper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.